Intra-Cellular Therapies Inc. (NASDAQ:ITCI) – Stock analysts at Leerink Swann lifted their FY2019 earnings estimates for Intra-Cellular Therapies in a research report issued on Thursday, according to Zacks Investment Research. Leerink Swann analyst P. Matteis now forecasts that the biopharmaceutical company will post earnings per share of ($1.89) for the year, up from their previous forecast of ($2.03).
ITCI has been the topic of a number of other research reports. Zacks Investment Research upgraded shares of Intra-Cellular Therapies from a “hold” rating to a “buy” rating and set a $16.00 target price on the stock in a research note on Wednesday, January 3rd. SunTrust Banks upgraded shares of Intra-Cellular Therapies from a “hold” rating to a “buy” rating in a research note on Wednesday, November 8th. BidaskClub cut shares of Intra-Cellular Therapies from a “sell” rating to a “strong sell” rating in a research note on Saturday, December 30th. Canaccord Genuity assumed coverage on shares of Intra-Cellular Therapies in a research note on Friday, December 15th. They set a “buy” rating and a $31.00 target price on the stock. Finally, ValuEngine cut shares of Intra-Cellular Therapies from a “sell” rating to a “strong sell” rating in a research note on Wednesday, September 27th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $26.11.
Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.53). The business had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $0.06 million. Intra-Cellular Therapies had a negative net margin of 28,038.35% and a negative return on equity of 27.40%. The company’s revenue was up 675.0% compared to the same quarter last year. During the same quarter last year, the company posted ($0.70) EPS.
Hedge funds have recently made changes to their positions in the business. Russell Investments Group Ltd. bought a new stake in shares of Intra-Cellular Therapies in the 3rd quarter worth about $101,000. SG Americas Securities LLC bought a new stake in shares of Intra-Cellular Therapies in the 2nd quarter worth about $103,000. Quantbot Technologies LP increased its holdings in shares of Intra-Cellular Therapies by 233.1% in the 3rd quarter. Quantbot Technologies LP now owns 8,614 shares of the biopharmaceutical company’s stock worth $135,000 after buying an additional 6,028 shares during the last quarter. Fred Alger Management Inc. bought a new stake in shares of Intra-Cellular Therapies in the 2nd quarter worth about $161,000. Finally, Voya Investment Management LLC increased its holdings in shares of Intra-Cellular Therapies by 16.0% in the 2nd quarter. Voya Investment Management LLC now owns 16,911 shares of the biopharmaceutical company’s stock worth $210,000 after buying an additional 2,338 shares during the last quarter. Institutional investors and hedge funds own 74.47% of the company’s stock.
In other Intra-Cellular Therapies news, Director Richard A. Lerner sold 7,000 shares of the business’s stock in a transaction on Monday, December 11th. The shares were sold at an average price of $15.09, for a total value of $105,630.00. Following the sale, the director now owns 8,621 shares in the company, valued at approximately $130,090.89. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Christopher D. Alafi purchased 10,000 shares of the firm’s stock in a transaction on Wednesday, November 22nd. The stock was bought at an average price of $15.55 per share, for a total transaction of $155,500.00. Following the purchase, the director now owns 744,466 shares in the company, valued at $11,576,446.30. The disclosure for this purchase can be found here. In the last quarter, insiders sold 49,410 shares of company stock worth $802,481. Corporate insiders own 21.00% of the company’s stock.
WARNING: “FY2019 EPS Estimates for Intra-Cellular Therapies Inc. (NASDAQ:ITCI) Raised by Leerink Swann” was originally reported by BBNS and is the property of of BBNS. If you are reading this news story on another domain, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this news story can be viewed at https://baseballnewssource.com/markets/fy2019-earnings-estimate-for-intra-cellular-therapies-inc-issued-by-leerink-swann-itci/1824063.html.
About Intra-Cellular Therapies
Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.